Published in final edited form as:

Tetrahedron Lett. 2010 March 31; 51(13): 1782–1785. doi:10.1016/j.tetlet.2010.01.105.

Synthesis and structure assignment of the minor metabolite arising from the frog pathogen *Mycobacterium liflandii*

Thomas Spangenberg, Sylvain Aubry, and Yoshito Kishi*

Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, MA 02138, USA

Abstract

Total synthesis and structure assignment of the minor metabolite present in lipid extracts of the frog pathogen *Mycobacterium liflandii* are reported.

Buruli ulcer is a devastating but neglected necrotizing skin disease caused by *Mycobacterium ulcerans* infection, the third most common mycobacteriosis in humans after tuberculosis (*M. tuberculosis*) and leprosy (*M. leprae*). It is noted that the occurrence of Buruli ulcer is increasing and spreading in tropical countries, and that the incidence of the disease may exceed that of leprosy and tuberculosis in highly affected areas. Infection with *M. ulcerans*, probably carried by aquatic insects, results in progressive necrotic lesions that can extend to 15% of a patient's skin surface if left untreated. At present, surgical intervention is the only realistic curative therapy for Buruli ulcer.ⁱ

Unlike the two most recognized pathogenic mycobacteria, *M. tuberculosis* and *M. leprae*, *M. ulcerans* was recognized to produce a small molecule toxin. In 1999, Small and co-workers isolated two toxins, designated as mycolactones A and B, from *M. ulcerans*.ⁱⁱ Mycolactones A and B are now known to exist as an equilibrating mixture of geometric isomers (Figure 1), and are referred to as mycolactone A/B in this paper.^{iii,iv,v} Intradermal inoculation of mycolactone A/B into guinea pigs produces a lesion similar to that of Buruli ulcer in humans, demonstrating their direct correlation with Buruli ulcer.^{vi}

Mycolactone A/B constitutes the major metabolite produced by West African strains of *M. ulcerans*. Several mycolactone congeners, including mycolactones C and D, were isolated from clinical isolates of *M. ulcerans* from Africa, Malaysia, Asia, Australia, and Mexico.^{vii,viii} Interestingly, a mycolactone-like metabolite was isolated from the fish pathogen *M. marinum* as well as *M. pseudoshottsii*, and displays stereochemical heterogeneity depending upon its living environment.^{ix,a}

Figure 1 lists all of the mycolactones whose complete structure has been established.^{3–5, 7b, 9b–c,11b} Interestingly, all of the mycolactones known to date are composed of a conserved 12-membered macrolactone core and a highly unsaturated fatty acid side chain that differs amongst the members of this class of natural products.

*Corresponding author. kishi@chemistry.harvard.edu.

Supplementary Material

Experimental details and ¹H and ¹³C NMR spectra.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

In 2004, a Buruli ulcer-like disease was reported in laboratory colonies of the West African clawed frog *Xenopus tropicalis* that had been imported to the United States.^x This disease, lethal to the frogs, is caused by infection with the pathogenic *M. liflandii*. In 2005, Small and co-workers succeeded in the isolation of a new mycolactone, called mycolactone E, and proposed its gross structure. Based on MS/MS analysis in combination with deuterium exchange and chemical transformation, Leadlay and co-workers suggested an alternative gross structure.^{xia} Using organic synthesis as the major tool, we established the complete structure of mycolactone E as shown in Figure 1.^{11b}

Interestingly, both Leadlay and Small noticed the presence of a minor metabolite present in lipid extracts of mycolactone E.^{11a} Mass spectroscopy analysis suggested that this minor metabolite shares the core structure with mycolactone E, but contains the polyunsaturated fatty acid in which one of the two hydroxyl groups found in mycolactone E is replaced by a ketone. Based on the MS/MS fragmentation pattern, in particular the fragment resulting from a characteristic McLafferty rearrangement, Leadlay and coworkers proposed the C13'-ketone structure for the minor metabolite. Coupled with the stereochemistry of mycolactone E recently established,^{11b} the proposed C13'-ketone is now translated to **1** (Figure 2). We are interested in confirming the proposed structure. In connection with this, we should mention a significant challenge encountered in the structure determination of mycolactone E; only a very minute amount of mycolactone E was available for that study.^{xii} Obviously, we have to face the same obstacle in the structure confirmation reported in this letter.

To establish the proposed structure, we decided to adopt the approach previously used for mycolactones.^{5,7b,9b,11b} This approach consisted of two steps, i.e., (1) to synthesize the proposed structure and (2) to compare the synthetic substance with the natural product. For a synthesis of **1**, we opted to follow the previous synthetic route; specifically we planned: (1) to couple the protected mycolactone core **2** with the suitably functionalized fatty acid **3** via Yamaguchi esterification, (2) to use a 1,3-dithiane as a synthetic equivalent with the C13'-ketone, and (3) to adopt an iterative Horner-Emmons olefination approach for introduction of the tetraenoic acid moiety (Scheme 1). We then recognized that the multicomponent anion-relay-chemistry is ideally suited for a synthesis of the key fragment **4** from commercially available (–)-epichlorohydrin.^{xiii}

The synthesis began with the reaction of (–)-epichlorohydrin (AK Scientific; optical purity: 99%) with vinylmagnesium bromide in the presence of a catalytic amount of copper iodide to yield the homoallylic alcohol which was converted to epoxide **5** by a KOH-treatment (83%, two steps). TBS-1,3-dithiane^{xiv} was deprotonated with *t*-BuLi and then reacted with epoxide **5** to initiate the anion-relay-chemistry. In the same pot, a [1,4]-Brook rearrangement was triggered upon addition of HMPA, and the newly generated dithiane anion was trapped with ethyl iodide to furnish the key fragment **4** in 64% yield. Dihydroxylation with OsO₄, followed by oxidative cleavage of the 1,2-diol, gave aldehyde **6** without significantly disturbing the dithiane group.^{xv} Next, a chain-elongation protocol consisting of (1) Horner-Emmons olefination, (2) DIBAL-H reduction, and (3) MnO₂ oxidation was repeatedly applied to obtain the protected unsaturated fatty acid ester **16** in excellent overall yield. Although cumbersome, we purposely adopted the iterative chain elongation approach to isolate, and characterize, a stereochemically homogeneous *E*-unsaturated ester in each cycle.^{9b,11b} In this synthesis, Horner-Emmons olefination gave the product with *E/Z*: 94/6 (1st cycle, **7**), 98/2 (2nd cycle, **10**), 98/2 (3rd cycle, **13**), and 95/5 (4th cycle, **16**). Finally, saponification of **16** with LiOH furnished the stereochemically homogeneous **3** in quantitative yield (Scheme 2).

Acid **3** was coupled with the protected core **2**^{xvi} under Yamaguchi esterification conditions, to furnish the fully protected mycolactone **17** in 91% yield (Scheme 3).

To complete the synthesis, we needed to deprotect the 1,3-dithiane and three TBS-groups. Through the first- and second-generation syntheses of mycolactone A/B,⁵ we learned that this natural product is relatively labile under acidic conditions, but perfectly stable under the conditions of TBAF-promoted TBS-deprotection. Based on this knowledge, we planned to cleave first the 1,3-dithiane and then the TBS-groups. Experimentally, we found that, upon treatment with silver nitrate and *N*-chlorosuccinimide,^{xvii} the 1,3-dithiane was cleanly removed to give the desired ketone **18** in 87% yield. However, deprotection of the three TBS-groups was problematic; under the standard TBAF conditions, deprotection stopped mainly at the mono-TBS stage or resulted in complete decomposition.^{xviii} After numerous attempts, we finally found that the desired deprotection was realized by treatment with excess TBAF (30 equiv) in THF (2 mM), followed by a CaCO₃/Dowex resin workup, to furnish completely deprotected **1** in 44% yield.^{xix} Unfortunately, this procedure was found problematic in a slightly larger scale (4 mg). Therefore, we conducted several small-scale experiments to obtain a sufficient amount of the synthetic **1** for full characterization and comparison with the natural product. Notably, the synthetic **1** was found to give a MS/MS spectrum, with the predominant peak being a loss of 2-butanone from the molecular ion *via* a McLafferty rearrangement, as reported for the natural product.

Our next task was to prove, or disprove, that the synthetic **1** is identical with the natural minor metabolite. Given only a very minute amount of the authentic sample dispensable for our study,¹² we needed a highly sensitive and reliable method. For the stereochemistry assignment of mycolactone F, we have developed such a method that relies on the chiral HPLC profile. In short, this method consisted of two steps, i.e., (1) to prepare a photochemically-equilibrated mixture of geometric isomers for a given mycolactone and (2) to perform structure analysis based on the distinct *HPLC profile* comprised of a set of peaks with different retention times, each peak corresponding to one geometric isomer present in the mixture.^{9b-c}

In this work, we subjected the synthetic **1** to photochemically-induced equilibration in acetone (Reonet, 300 nm for 2 min), to yield a *ca.* 1:1:1 mixture of three major geometric isomers (all-*trans*-, *Z*- $\Delta^{4',5'}$ -, and *Z*- $\Delta^{6',7'}$ -isomers, thick red dashed lines),^{9b,11b} along with three minor isomers (thin red dashed lines). We found that Chiralpak IA chiral column gave an excellent separation of all the geometric isomers, yielding its HPLC profile (Figure 3, panel A). Under the same conditions, synthetic mycolactone E exhibited a different HPLC profile (Figure 3, panel B, blue dashed lines). In addition, a co-injection of synthetic **1** and mycolactone E demonstrated that their HPLC profiles are clearly distinguishable from each other (Figure 3, panel C).

With this foundation, we compared the synthetic **1** with the minor metabolite of the frog pathogen *M. liflandii*. For this comparison, we used the same batch of *M. liflandii* lipid extract as the one used for the mycolactone E study.^{9b,12} By MS analysis, this lipid extract was shown to contain both mycolactone E and the minor metabolite. In addition, mycolactone E contained in this extract was demonstrated to be a mixture of geometric isomers with the ratio virtually identical to that found in the photochemically-equilibrated synthetic sample. Thus, we assumed that the minor metabolite in this mixture is also a mixture of geometric isomers. Panel D in Figure 3 shows the HPLC behavior of this sample, demonstrating that both HPLC profiles, one characteristic to mycolactone E and the other characteristic to the minor metabolite, are clearly detectable. This conclusion is further supported by co-injection of the synthetic **1** and the crude lipid extract (Figure 3, panel E). Overall, these experiments establish that the minor metabolite present in the crude lipid extract of the frog pathogen *M. liflandii* is represented by the structure **1**.

The mycolactone class of natural products is known to exhibit a variety of biological activities. ^{1f} Synthetic **1** exhibited cytotoxicity (GI₅₀: 15 nM) against L929 murine fibroblast cells that is practically identical to that of synthetic mycolactone E.^{xxi}

In conclusion, we have established the complete structure of the minor metabolite present in lipid extracts of the frog pathogen *M. liflandii*. In this work, we have used synthetic **1** to characterize the HPLC profile, which is then used for structure analysis of the natural product.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Professor Pam Small at University of Tennessee for the generous gift of lipid extracts of the frog pathogen *M. liflandii*. We are grateful to the National Institutes of Health (CA 22215) and Eisai USA Foundation for generous financial support.

References and Notes

- i. For general reviews on Buruli ulcer, for example see: (a) Asiedu, K.; Scherpbier, R. Buruli ulcer: Mycobacterium ulcerans infection. Ravignione, M., editor. World Health Organization; Geneva, Switzerland: 2000. (b) van der Werf TS, Stinear T, Stienstra Y, van der Graaf WTA, Small PL. Lancet 2003;362:1062. [PubMed: 14522538] (c) Johnson PDR, Stinear T, Small PLC, Pluschke G, Merritt RW, Portaels F, Huygen K, Hayman JA, Asiedu K. PLoS Med 2005;2:e108. [PubMed: 15839744] (d) van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, Fleischer B, Wansbrough-Jones MH, Johnson PDR, Portaels F, van der Graaf WTA, Asiedu K. Bull World Health Org 2005;83:785. [PubMed: 16283056] (e) Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T. Nat Prod Rep 2008;447. [PubMed: 18497894] (f) Demangel C, Stinear TP, Cole ST. Nat Rev Microbiol 2009;7:50. [PubMed: 19079352]
- ii. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, Small PLC. Science 1999;283:854. [PubMed: 9933171]
- iii. For the gross-structure of mycolactone A/B, see: Gunawardana G, Chatterjee D, George KM, Brennan P, Whittern D, Small PLC. J Am Chem Soc 1999;121:6092.
- iv. For the stereochemistry of mycolactone A/B, see: (a) Benowitz AB, Fidanze S, Small PLC, Kishi Y. J Am Chem Soc 2001;123:5128. [PubMed: 11457356] (b) Fidanze S, Song F, Szlosek-Pinaud M, Small PLC, Kishi Y. J Am Chem Soc 2001;123:10117. [PubMed: 11592899]
- v. For the total synthesis of mycolactone A/B, see: Song F, Fidanze S, Benowitz AB, Kishi Y. Org Lett 2002;4:647. [PubMed: 11843613] Tetrahedron 2007;63:5739. [PubMed: 17940589]
- vi. George KM, Pascopella L, Welty DM, Small PLC. Infect Immun 2000;68:877. [PubMed: 10639458]
- vii. For mycolactone C, see: (a) the isolation and gross-structure: Mve-Obiang A, Lee RE, Portaels F, Small PLC. Infect Immun 2003;71:774. [PubMed: 12540557] the stereochemistry and total synthesis: (b) Judd TC, Bischoff A, Kishi Y, Adusumilli S, Small PLC. Org Lett 2004;6:4901. [PubMed: 15606095]
- viii. Hong H, Spencer JB, Porter JL, Leadlay PF, Stinear T. ChemBioChem 2005;6:643. [PubMed: 15750996]
- ix. For mycolactone F, see: (a) isolation and gross-structure: Ranger BS, Mahrous EA, Mosi L, Adusumilli S, Lee RE, Colorni A, Rhodes M, Small PLC. Infect Immun 2006;74:6037. [PubMed: 16923788] Hong H, Stinear T, Porter J, Demangel C, Leadlay PF. ChemBioChem 2007;8:2043. [PubMed: 17907121] (b) stereochemistry and total synthesis of mycolactone F isolated from the saltwater fish pathogen *M. marinum*: Kim HJ, Kishi Y. J Am Chem Soc 2008;130:1842. [PubMed: 18205366] (c) stereochemistry and total synthesis of mycolactone F isolated from the freshwater fish pathogen *M. marinum*: Kim HJ, Jackson KL, Kishi Y, Williamson HR, Mosi L, Small PLC. Chem Commun 2009:7402.

- x. Trott KA, Stacy BA, Lifland BD, Diggs HE, Harland RM, Khokha MK, Grammer TA, Parker JM. *Comp Med* 2004;54:309. [PubMed: 15253278]
- xi. For mycolactone E, see: (a) isolation and gross-structure: Hong H, Stinear T, Skelton P, Spencer JB, Leadlay PF. *Chem Commun* 2005:4306. Mve-Obiang A, Lee RE, Umstot ES, Trott KA, Grammer TC, Parker JM, Ranger BS, Grainger R, Mahrous EA, Small PLC. *Infect Immun* 2005;73:3307. [PubMed: 15908356] (b) stereochemistry and total synthesis: Aubry S, Lee RE, Mahrous EA, Small PLC, Beachboard D, Kishi Y. *Org Lett* 2008;10:5385. [PubMed: 18975952]
- xii. We used the lipid extract from fermentation broth of *M. liflandii* donated by Professor Pam Small.
^{10a} The total amount of mycolactones present in this extract was estimated to be equivalent with ~10 injections for HPLC analysis.
- xiii. For a recent review on Anion-Relay-Chemistry see: Smith AB III, Wuest WM. *Chem Commun* 2008:5883.
- xiv. For the preparation of TBS-1,3-dithiane see: Silverman RB, Lu X, Banik GM. *J Org Chem* 1992;57:6617.
- xv. For dihydroxylation of sulphur containing substrates, see for example: (a) Walsh PJ, Ho PT, King SB, Sharpless KB. *Tetrahedron Lett* 1994;35:5129. (b) Sammakia T, Hurley B, Sammond DM, Smith RS, Sobolov SB, Oeschger TR. *Tetrahedron Lett* 1996;37:4427.
- xvi. The core alcohol **2** was synthesized by Dr. Han-Je Kim in this laboratory.
- xvii. Corey EJ, Erickson BW. *J Org Chem* 1971;36:3553.
- xviii. TBAF tested included: TBAF (Aldrich) as supplied and TBAF buffered with imidazole hydrochloride and AcOH.
- xix. Kaburagi Y, Kishi Y. *Org Lett* 2007;9:723. [PubMed: 17286380]
- xx. Using the initial solvent conditions described for mycolactone E (benzene: EtOH 98.5:1.5) resulted in the overlap of several peaks, see Supporting Information.
- xxi. This test was performed by Dr. Katrina L. Jackson in this laboratory. The complete data will be reported elsewhere.

Mycolactone Unsaturated Fatty Acid Side Chains

Isolated from human pathogen *M. ulcerans*

mycolactone A/B: X=OH; R=H

mycolactone C: X=H; R=H

mycolactone D: X=OH; R=Me

Isolated from frog pathogen *M. liflandii*

mycolactone E

Isolated from saltwater fish pathogen *M. marinum*

mycolactone F

Isolated from freshwater fish pathogen *M. marinum*

mycolactone *dia*-F

Figure 1.
Structures of the mycolactones.

Figure 2.
Proposed complete structure of the minor metabolite present in a crude lipid extract of the frog pathogen *M. liflandii*.

Figure 3.

Chiral HPLC analysis. Analytical conditions: column: Chiral Tech, Chiralpak IA (5 μ m), 250 $\times$ 4.6 mm; solvent (isocratic): toluene/ethanol 98.5/1.5^{xx}; flow rate: 1 mL/min; detection: UV at 323 nm. Panel A: synthetic **1**; Panel B: synthetic mycolactone E; Panel C: *ca* 1:1 mixture of synthetic **1** and mycolactone E; Panel D: lipid extract of *M. liflandii*; Panel E: *ca* 1:1 mixture of synthetic **1** and lipid extract of *M. liflandii*.

Scheme 1.

Overall plan for a total synthesis of the minor metabolite **1**. Abbreviation: TBS = *t*-Bu (Me)₂Si-.

Scheme 2.

Synthesis of the protected unsaturated fatty acid. a) vinylMgBr, CuI cat. Et₂O, -78 °C to -40 °C, 92%, *ee*: >95% estimated from ¹H NMR of its Mosher ester. b) KOH, distillation (90 °C, atm pressure), 91%. c) *t*-BuLi, TBS-1,3-dithiane, HMPA, EtI, -78 °C to -25 °C, 64%. d) OsO₄, K₃(CN)₆, DABCO, MeSO₂NH₂, *t*-BuOH/H₂O, 0 °C. e) Pb(OAc)₄, PhH, 0 °C, 57% (2 steps). f) EtO₂CCH(Me)P(O)(OEt)₂, *n*-BuLi, LiBr, MeCN, 0 °C to rt, 94% (*E/Z*: 94/6). g) and g') DIBAL-H, DCM, -78 °C; MnO₂, DCM, rt; EtO₂CCH(Me)P(O)(OEt)₂, *n*-BuLi, THF, 0 °C to rt, 72–92% over 3 steps (*E/Z*: 98/2). g'') DIBAL-H, DCM, -78 °C; MnO₂, DCM, rt; EtO₂CCH₂P(O)(OEt)₂, *n*-BuLi, THF, 0 °C to rt, 95% over 3 steps (*E/Z*: 95/5). h) LiOH, THF/MeOH/H₂O, rt, quant. Abbreviation: TBS = *t*-Bu(Me)₂Si-; H-E = Horner-Emmons olefination.

Scheme 3.

Completion of the synthesis. a) 1,3,5-trichlorobenzoylchloride, DMAP, *i*-Pr₂NEt, PhH, rt, 91%. b) NCS, AgNO₃, 2,6-lutidine, MeCN/H₂O, 0 °C, 10–15 sec, 87%. c) TBAF, THF, rt, 44%. Abbreviation: TBS = *t*-Bu(Me)₂Si-.